Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

By G. Järnerot, E. Hertervig, I. Friis-Liby, L. Blomquist, P. Karlén, C. Grännö, M. Vilién, M. Ström, Å. Danielsson, H. Verbaan and 3 more. Gastroenterology, 2005

1,135 citations recorded by the source corpus.

Subfields: Epidemiology, Genetics, Hepatology

View Paper: https://www.semanticscholar.org/paper/4e03071f11f64e7225e2851daea5166fc2c75b52

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. W. Sandborn
2. J. Colombel
3. S. Hanauer
4. Stefan Schreiber
5. Markus F. Neurath

In Genetics

1. W. Sandborn
2. Stefan Schreiber
3. J. Colombel
4. S. Hanauer
5. G. Lichtenstein
6. B. Feagan
7. P. Rutgeerts
8. Bruce E. Sands

Citations in the corpus

• Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee (2010, background): “In one double-blind series of 45 patients, patients with either fulminant colitis at day 3, or severe colitis at days 6–8, despite continued intravenous steroids, were randomized to either a single dose of infliximab 5 mgskg or placebo (”
• European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. (2008, neutral): “5 (73), 0 (35) 4 Response 45% vs 45% (6.”
• Guidelines for the management of inflammatory bowel disease in adults (2011, background): “in a RCT involving 45 patients comparing a single infusion of IFX (5 mg/kg) and placebo showed significantly lower colectomy rates within 90 days of therapy (primary end-point; p=0.017, OR 4.9).”
• Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial (2011, background): “in an attempt to increase treatment options and improve clinical outcomes, but only the chimeric monoclonal anti-tumour necrosis factor α (TNFα) antibody, infliximab, has been shown to induce and maintain remission in patients with moderate to severe ulcerative colitis.”
• Infliximab for induction and maintenance therapy for ulcerative colitis. (2005, methodology): “[19-23] We therefore conducted 54-week and 30-week studies of infliximab in patients with moderate-to-severe ulcerative colitis: the Active Ulcerative Colitis Trials 1 and 2 (ACT 1 and 2, respectively).”